Previous Article | Next Article 
Journal of Clinical Microbiology, October 2005, p. 5272-5274, Vol. 43, No. 10
0095-1137/05/$08.00+0 doi:10.1128/JCM.43.10.5272-5274.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Decay of Human Immunodeficiency Virus Type 1 Unintegrated DNA Containing Two Long Terminal Repeats in Infected Individuals after 3 to 8 Years of Sustained Control of Viremia
Jennifer L. McDermott,1,3
Isabella Martini,1,3
Davide Ferrari,1,3
Francesca Bertolotti,1
Claudio Giacomazzi,1,3
Giuseppe Murdaca,2
Francesco Puppo,2
Francesco Indiveri,2 and
Oliviero E. Varnier1,3*
Sections of Microbiology,1
Internal Medicine and Clinical Immunology, School of Medicine, University of Genova,2
Diagnostic Microbiology of Infectious Diseases, Advanced Biotechnology Center, Genova, Italy3
Received 10 January 2005/
Returned for modification 22 April 2005/
Accepted 4 August 2005

ABSTRACT
Covert human immunodeficiency virus (HIV) replication was ongoing
during the first 3 years of aviremia in 22 patients, as determined
by detection of DNA containing two long terminal repeats (2LTR
DNA). Although total HIV DNA was detected in 60 2LTR DNA-negative
samples, the absence of 2LTR DNA in 90% of patients following
7 to 8 years of highly active antiretroviral therapy suggests
suppression of cryptic viral replication.

TEXT
Measurement of plasma RNA levels is considered the best prognostic
marker for predicting clinical outcome in human immunodeficiency
virus type 1 (HIV-1) infection and is also a marker of therapy
efficacy. Treatment guidelines suggest that viremia should be
measured every 3 to 6 months in treated patients (
14), yet following
highly active antiretroviral therapy (HAART), viremia is drastically
reduced to undetectable levels and the treatment strategy is
focused on maintaining this aggressive and seemingly efficient
therapy for the longest possible period (
12). The existence
of latent reservoirs of integrated proviral DNA in resting CD4
+ T lymphocytes provides a long-lived source of replication-competent
virus in patients undergoing potent HAART (
3,
5,
13,
17). In
the absence of integration, the extrachromosomal viral DNA can
remain in the linear form or circularize to produce circular
DNA forms containing one or two long terminal repeats (LTRs),
respectively (
1,
15). It was thought that unintegrated DNA had
a transient existence in infected cells due to its rapid degradation
once formed (
16) and that its detection was consistent with
de novo infection. The accumulation of unintegrated DNA was
observed in infected individuals with high plasma RNA levels
(
10), and several studies evaluated the use of DNA containing
two LTRs (2LTR DNA) as a marker for HIV disease progression
(
11,
18). A decrease in 2LTR DNA levels was seen in a group
of patients following the initiation of antiretroviral therapy
(
4) in correlation with therapy efficacy, and later studies
used 2LTR assays to monitor ongoing viral replication in subjects
with suppressed plasma viremia (
2,
8). However, few studies
document whether HAART is able to arrest covert virus replication
in well-suppressed patients.
The objective of this study was to monitor HIV total DNA and unintegrated 2LTR DNA levels in peripheral blood mononuclear cells (PBMCs) from aviremic subjects receiving HAART for very long periods and to assess whether there was a correlation between cryptic HIV replication, total DNA, and unintegrated 2LTR DNA levels.
Three hundred twenty-six sequential PBMC samples were obtained from 22 aviremic subjects on HAART during an 8-year period. The PBMCs were separated from whole blood, and total cellular DNA was extracted by cell lysis as previously described (7). The cell lysates were stored at 20°C until assayed. The amplification, detection, and quantification of HIV total DNA were performed using a previously described colorimetric assay (6, 9). For the detection of unintegrated 2LTR DNA, the U3-U5 junction between the two LTRs was amplified in a final reaction volume of 100 µl containing 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl2, 200 µM deoxynucleoside triphosphates (dNTPs), 0.15 µM each of primer 477 and biotinylated primer 516 (1), 1.5 U of Taq DNA polymerase, and 50 µl of cell lysate sample. Following an initial denaturation step of 95°C for 2 min, amplification proceeded for a total of 50 cycles: 5 cycles at 95°C for 10 s, 60°C for 10 s, and 72°C for 10 s; 45 cycles at 94°C for 10 s, 55°C for 10 s, and 72°C for 10 s; and a final extension at 72°C for 5 min. Two LTR PCR products were detected by hybridization to a fluorescein-labeled specific probe, 569 (1), followed by colorimetric detection (9).
Total HIV DNA was quantified in 188 (58%) samples, in a range from 53 to 27,386 HIV copies/106 PBMCs (data not shown), and was undetectable in the remaining 138 samples. Unintegrated 2LTR DNA was detectable in 103 (32%) samples and undetectable in 218 samples (Table 1). At the end of the 2nd year, one patient had interrupted day hospital attendance and three patients had died.
A two-time-point analysis of HIV total DNA levels was assessed
in the remaining 18 patients by using the levels obtained in
the first (
t1) and last (
t2) samples analyzed. As shown in Fig.
1, very high DNA levels (>2,000 copies/10
6 PBMCs, corresponding
to 1 HIV-positive cell every 230 to 400 PBMCs) were observed
at
t1 in three patients and high levels (>1,000 DNA copies/10
6 PBMCs, corresponding to 1 HIV-positive cell every 690 to 950
PBMCs) were observed in five patients. Low levels of HIV DNA
ranging from 185 to 871 DNA copies/10
6 PBMCs (1 positive cell
every 1,148 to 5,405 PBMCs) were quantified in six patients,
while undetectable levels of total HIV DNA (<50 DNA copies/10
6 PBMCs) were observed in four subjects. At
t2, 11 subjects had
undetectable total DNA levels (<50 copies/10
6 PBMCs), 4 patients
had low DNA levels (99 to 447 DNA copies/10
6 PBMCs), and 2 patients
had high DNA levels (1,149 and 1,411 DNA copies/10
6 PBMCs, respectively).
Very high total DNA levels (3,904 DNA copies/10
6 PBMCs) were
observed only for one patient who interrupted therapy due to
pregnancy.
The numbers of samples positive for HIV total DNA and unintegrated
2LTR DNA were analyzed comparatively as depicted in Fig.
2.
Fifty-five percent of the samples examined had detectable total
DNA levels after 8 years of aviremia. In contrast, although
2LTR DNA was detectable in approximately 50% of the samples
during the first 3 years, the percentage of positive samples
dropped drastically to 6% at the end of the 4th year and 2LTR
DNA remained detectable in a small percentage of samples until
the end of the study period. During this period, 2LTR DNA was
undetectable in 60 (82%) of the 73 cell lysate samples analyzed,
which all had detectable total DNA levels. Overall, the longitudinal
monitoring of total HIV and unintegrated 2LTR DNA in patients
revealed a general decay for HIV DNA levels to undetectable
levels.
The two-time-point analysis of total HIV DNA levels showed that
at the end of the observation period, the majority of patients
(83%) monitored had undetectable or low total DNA levels, while
very high or high DNA levels were quantified in only 3 (17%)
patients. This decay in the number of infected cells suggests
that long-term potent antiretroviral therapy may efficiently
suppress HIV cryptic replication and maintain persistent aviremia
leading to a regression of HIV infection.
At the start of this study, unintegrated 2LTR DNA was detectable in 56% of the patients monitored. After 3 years of HAART, a dramatic decrease was observed in the number of samples with detectable 2LTR DNA, and after 8 years of uninterrupted therapy, 2LTR DNA was detectable in only 9% of the tested samples. These observations support the concept that 2LTR circles are labile and do not persist over time.
Our findings indicate that covert HIV replication was ongoing during the first 3 years of follow-up, confirmed by the detection of 2LTR circles, produced by HIV de novo infection. The absence of 2LTR DNA in the majority of our patients following 7 to 8 years of HAART appears to be due to suppression of cryptic viral replication, which is confirmed by the presence of detectable total HIV DNA in approximately 80% of the 2LTR DNA-negative samples. Cryptic replication seems to be almost completely suppressed after 3 years of HAART, suggesting that both total and unintegrated 2LTR DNA forms could be useful markers for the monitoring of regression of HIV infection in aviremic patients.

ACKNOWLEDGMENTS
This work was partially supported by the Italian AIDS Program
of the Istituto Superiore di Sanità (grant no. 34B.7
to O.E.V. and SP7.2 to J.L.M.) and a CIPE grant from the Advanced
Biotechnology Center of Genova to O.E.V.

FOOTNOTES
* Corresponding author. Mailing address: Section of Microbiology, University of Genova School of Medicine, Largo Rosanna Benzi, 10, 16132 Genova (EC), Italy. Phone: 39 010 353-7649. Fax: 39 010 353-7698. E-mail:
oliviero.varnier{at}unige.it.


REFERENCES
1 - Cara, A., and M. S. Reitz, Jr. 1997. New insight on the role of extrachromosomal retroviral DNA. Leukemia 11:1395-1399.[CrossRef][Medline]
2 - Cara, A., J. Vargas, Jr., M. Keller, S. Jones, A. Mosoian, A. Gurtman, A. Cohen, V. Parkas, F. Wallach, E. Chusid, I. H. Gelman, and M. E. Klotman. 2002. Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. Virology 292:1-5.[CrossRef][Medline]
3 - Chun, T. W., D. Finzi, J. Margolick, K. Chadwick, D. Schwartz, and R. F. Siliciano. 1995. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1:1284-1290.[CrossRef][Medline]
4 - Donovan, R. M., C. E. Bush, S. M. Smereck, D. M. Baxa, N. P. Markowitz, and L. D. Saravolatz. 1994. Rapid decrease in unintegrated human immunodeficiency virus DNA after the initiation of nucleoside therapy. J. Infect. Dis. 170:202-205.[Medline]
5 - Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV in patients on highly active antiretroviral therapy. Science 278:1295-1300.[Abstract/Free Full Text]
6 - Giacomini, M., J. L. McDermott, A. A. Giri, I. Martini, F. B. Lillo, and O. E. Varnier. 1998. A novel and innovative quantitative kinetic software for virological colorimetric assays. J. Virol. Methods 73:201-209.[CrossRef][Medline]
7 - Giri, A. A., F. B. Lillo, J. L. McDermott, C. Jannuzzi, S. Risso, G. L. Fornia, D. R. Concedi, and O. E. Varnier. 1994. Detection of HIV-1 sequences in children using radioactive and colorimetric polymerase chain reactions. J. Med. Virol. 42:414-419.[Medline]
8 - Hauber, I., T. Harrer, P. Low, M. Schmitt, E. Schwingel, and J. Hauber. 2000. Determination of HIV-1 circular DNA as a surrogate marker for residual virus replication in patients with undetectable virus loads. AIDS 14:2619-2621.[CrossRef][Medline]
9 - McDermott, J. L., A. A. Giri, I. Martini, M. Bono, M. Giacomini, A. Campelli, L. Tagliaferro, A. Cara, and O. E. Varnier. 1999. Level of human immunodeficiency virus DNA in peripheral blood mononuclear cells correlates with efficacy of antiretroviral therapy. J. Clin. Microbiol. 37:2361-2365.[Abstract/Free Full Text]
10 - Panther, L. A., R. W. Coombs, S. A. Aung, C. Della Rosa, D. Gretch, and L. Corey. 1999. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro. J. Med. Virol. 58:165-173.[CrossRef][Medline]
11 - Pauza, C. D., P. Trivedi, T. S. McKechnie, D. D. Richman, and F. M. Graziano. 1994. 2LTR circular viral DNA as a marker of human immunodeficiency virus type 1 infection in vivo. Virology 205:470-478.[CrossRef][Medline]
12 - Perelson, A. S., P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz, and D. D. Ho. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191.[CrossRef][Medline]
13 - Pomerantz, R. J. 2001. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clin. Infect. Dis. 34:91-97.
14 - Saag, M. S., M. Holodniy, D. R. Kuritzkes, W. A. O'Brien, R. Coombs, M. E. Poscher, D. M. Jacobsen, G. M. Shaw, D. D. Richman, and P. A. Volberding. 1996. HIV viral load markers in clinical practice. Nat. Med. 2:625-629.[CrossRef][Medline]
15 - Sharkey, M. E., and M. Stevenson. 2001. Two long terminal repeat circles and persistent HIV-1 replication. Curr. Opin. Infect. Dis. 14:5-11.[CrossRef][Medline]
16 - Stevenson, M., S. Haggerty, C. A. Lamonica, C. M. Meier, S.-K. Welch, and A. J. Wasiak. 1990. Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. J. Virol. 64:2421-2425.[Abstract/Free Full Text]
17 - Wong, J. K., M. Hezareh, H. F. Gunthard, D. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1294.[Abstract/Free Full Text]
18 - Zazzi, M., L. Romano, M. Catucci, G. Venturi, A. De Milito, P. Almi, A. Gonnelli, M. Rubino, U. Occhini, and P. E. Valensin. 1997. Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression. J. Med. Virol. 52:20-25.[CrossRef][Medline]
Journal of Clinical Microbiology, October 2005, p. 5272-5274, Vol. 43, No. 10
0095-1137/05/$08.00+0 doi:10.1128/JCM.43.10.5272-5274.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Cara, A., Klotman, M. E.
(2006). Retroviral E-DNA: persistence and gene expression in nondividing immune cells. J. Leukoc. Biol.
80: 1013-1017
[Abstract]
[Full Text]